HC Wainwright Issues Pessimistic Outlook for JBIO Earnings

Jade Biosciences, Inc. (NASDAQ:JBIO) – Investment analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for Jade Biosciences in a research report issued on Wednesday, March 25th. HC Wainwright analyst A. He now expects that the company will post earnings per share of ($0.50) for the quarter, down from their prior estimate of ($0.41). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. HC Wainwright also issued estimates for Jade Biosciences’ Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($2.02) EPS, Q1 2027 earnings at ($0.52) EPS, Q2 2027 earnings at ($0.52) EPS, Q3 2027 earnings at ($0.52) EPS, Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($2.09) EPS.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings data on Friday, March 6th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.34.

Several other research firms have also recently issued reports on JBIO. Lifesci Capital upgraded shares of Jade Biosciences to a “strong-buy” rating in a report on Friday, March 6th. Stifel Nicolaus set a $40.00 target price on Jade Biosciences in a report on Friday, March 6th. Zacks Research downgraded Jade Biosciences from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 29th. Finally, William Blair upgraded Jade Biosciences to a “strong-buy” rating in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Jade Biosciences has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Jade Biosciences Trading Down 4.0%

Jade Biosciences stock opened at $13.39 on Friday. Jade Biosciences has a 52 week low of $6.57 and a 52 week high of $100.10. The stock has a market cap of $660.39 million, a price-to-earnings ratio of -2.91 and a beta of 1.03. The company’s 50-day moving average price is $14.67 and its two-hundred day moving average price is $12.54.

Institutional Trading of Jade Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in JBIO. Geode Capital Management LLC acquired a new stake in Jade Biosciences during the second quarter valued at approximately $6,759,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Jade Biosciences in the second quarter worth approximately $71,000. Intech Investment Management LLC acquired a new position in Jade Biosciences in the second quarter worth approximately $230,000. JPMorgan Chase & Co. bought a new position in shares of Jade Biosciences in the second quarter valued at $154,000. Finally, Legal & General Group Plc bought a new position in shares of Jade Biosciences in the second quarter valued at $29,000.

More Jade Biosciences News

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $35.00 price target, showing continued analyst conviction and providing a clear upside reference for investors.
• Positive Sentiment: Media coverage highlights the analyst optimism (expectation of a share rise), reinforcing the bullish narrative from HC Wainwright. Jade Biosciences (NASDAQ:JBIO) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: HC Wainwright published detailed quarterly and annual EPS forecasts for 2026–2027 (typical biotech coverage data): ~($0.50) per quarter through 2026–2027 and FY2026/FY2027 EPS around ($2.02)/($2.09). These figures are useful for financial modeling and cash‑runway assumptions.
• Negative Sentiment: HC Wainwright lowered several near‑term EPS estimates: Q1 2026 cut from ($0.41) to ($0.50), Q2 2026 from ($0.42) to ($0.50), Q3 2026 from ($0.44) to ($0.51), Q4 2026 from ($0.46) to ($0.51). Those downgrades signal weaker near‑term operating or development visibility and are a likely driver of the share weakness.
• Negative Sentiment: The firm also reduced FY estimates (FY2026 from ($1.74) to ($2.02); FY2027 from ($2.05) to ($2.09)), increasing expected losses and pressure on near‑term valuation metrics.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.